ClinicalTrials.gg
CompletedNCT00497523Updated Aug 3, 2020

Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms

A Phase 3 interventional study of Beclomethasone dipropionate and Beclomethasone dipropionate/Salbutamol combination in Bronchial Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 19 sites in 2 countries. Open to participants aged 1 Year to 4 Years. Per ClinicalTrials.gov, last updated 2020-08-03.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
283
Allocation
Randomized
Ages
1 Year to 4 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
13th of 40
283 · median 67
Started
2006
with 1 other
Phase 3
20 of 40
none open now
Registered
11th of 40
by date
Lead sponsor
12 of 40
Chiesi Farmaceutici S.p.A.

Among the 40 studies testing beclomethasone in Asthma, this one is the 13th largest by enrollment, is one of 2 that started in 2006, is one of 20 in phase 3, and was the 11th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 1 Year to 4 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

To demonstrate a superior efficacy of BDP plus rescue salbutamol suspension for nebulisation, compared to placebo plus rescue salbutamol, in the relief of symptoms of asthma in young children with persistent symptoms of asthma.

Read the detailed description

Asthma is a chronic disease which is estimated to affect over 25 million people both in the US and Europe(i.e. approximately 10% of the total population).There is evidence that over the last 20 years prevalence has considerably increased, especially among children. The diagnosis of asthma in children may be difficult, largely because episodic wheezing and cough are among the common symptoms encountered in childhood illnesses, particularly in children under 3 years old.Although in these young children there is the possibility of over treatment, the episodes of wheezing may be reduced in intensity by the effective use of anti-inflammatory medications and bronchodilators rather than antibiotics. At present, pharmacological therapy is used to treat reversible airway obstruction, inflammation and hyperreactivity in both children and adults. Medications include preventive treatments in forms of antinflammatory/antiallergic agents (e.g. glucocorticosteroids, leukotriene antagonists, cromolyn sodium) and reliever treatments, in form of bronchodilators (e.g. β-adrenergic agonists, anticholinergics). Comparisons: Beclomethasone suspension for nebulisation (400 mcg U.D.V.) plus as needed salbutamol compared to placebo plus as needed salbutamol and to as needed salbutamol/beclomethasone fixed combination.

03

Conditions studied

  • Bronchial Asthma

Browse trials for

Keywords

  • Asthma
  • Young Children
  • Corticosteroids
  • Beclomethasone
  • Salbutamol
  • Beclomethasone/Salbutamol fixed combination
  • Suspension for nebulisation
04

Who can participate

Ages eligible
1 Year to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients will be enrolled into the 2-week placebo run-in period if they meet all the following criteria:

  • Age ≥ 1 year and ≤ 4 years.
  • At least 3 episodes of wheeze or asthma-like symptoms in the 6 months preceding the study entry.
  • A cooperative attitude and ability to be trained to inhale correctly from the device and to complete the diary cards.
  • Written parental/guardian obtained.

Patients will be then randomised to the treatment period if they meet all the previous criteria plus:

  • Presence in at least 7 days out of the 14 days of the run-in period of at least one of the following symptoms: wheeze, cough or shortness of breath; or had required at least one dose of relief salbutamol.

Exclusion criteria

Exclusion Criteria:

  • History of severe asthma exacerbation or exacerbations requiring hospitalisation in the previous 4 weeks.
  • Symptomatic infection of the airways requiring treatment with antibiotics or antimycotics in the previous 4 weeks.
  • Treatment with inhaled in the previous 4 weeks or oral steroids in the previous 8 weeks.
  • Treatment with methyl-xantine derivatives in the previous 4 weeks.
  • Treatment with long-acting β2-agonists in the previous 2 weeks.
  • Changes in asthma medications taken on regular basis in the previous 4 weeks.
  • Symptoms of asthma limited to seasonal allergen exposure.
  • History of cardiac, renal, neurologic, hepatic, endocrine or pulmonary disease (except asthma), or laboratory testing abnormalities, whose sequelae and/or treatments can interfere with the results of the present study.
  • Evidence of pulmonary malformations.
  • Evidence of immunological deficiency (patients to be withdrawn if diagnosed during the study).
  • Cancer or any other chronic disease with prognosis \< 2 years.
  • to inhaled corticosteroids.
  • Participation in another trial in the last 4 weeks.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
283 participants (actual)

Study arms

  • Experimental
    Beclomethasone dipropionate

    Drug: Beclomethasone dipropionate

  • Experimental
    Beclomethasone dipropionate/Salbutamol combination

    Drug: Beclomethasone dipropionate/Salbutamol combination

  • Active comparator
    Salbutamol

    Drug: Salbutamol

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of global (weeks 1-12) symptom-free days.

    Time frame: weeks 1-12

Secondary outcomes

  1. Frequency and number of exacerbations (defined as a worsening of symptoms of asthma requiring extra oral or inhaled corticosteroids)

    Time frame: weeks 1-12

  2. Single clinical symptoms

    Time frame: weeks 1-12 and every 2-week period

  3. Nocturnal awakening due to symptoms of asthma

    Time frame: weeks 1-12 and every 2-week period

  4. Use of rescue nebulised therapy

    Time frame: weeks 1-12 and every 2-week period

  5. time to first exacerbation

    Time frame: weeks 1-12

07

Study locations

19 sites
  • Zaklad Alergologii Dzieciecej
    Bialystok, Poland
  • Specjalistyczne Centrum Leczenia Dzieci i Mlodziezy
    Krakow, Poland
  • Wojskovy Szpital Klinikzny
    Krakow, Poland
  • Priwatna Pomoc Lekarska
    Lodz, Poland
  • Alergovita, alergologia Dziecieca
    Lublin, Poland
  • Priwtny Gabinet Pediatriczno - Alergologiczny
    Rabka Zdroj, Poland
  • City Children's Clinical Hospital n. 2, Dniepropetrovs'k State Medical Academy, Department of preliminary study of childhood disesas
    Dniepropetrovsk, Ukraine
  • Dniepropetrovsk Regional Children's Clinical Hospital, State Medical Academy, Hospital Paediatric Department N.1
    Dniepropetrovsk, Ukraine
  • Department of Hospital Pediatrics, Kharkiv State Medical University Region Clinical Children's Hospital n. 2
    Kharkiv, Ukraine
  • Respiratory Diseases Children's Clinic, Institute of Phthisiology and Pulmonology,Academy of Medical Science of the Ukraine, Pulmonology
    Kiev, Ukraine
  • Children's Hospital "OHMATDYT" Department of Pediatrics N. 1 of Kyiv Medical Academy of Postgraduate Education
    Kyiv, Ukraine
  • Department of Clinical rehabilitation of children with bodily diseasesof Institute of Pediatrics, Obstetrics and Gynecology
    Kyiv, Ukraine
  • Institute of Pediatrics, Obstetrics and Gynecology. Department of Children's Pulmonology Diseases and Ecological Problems of Health
    Kyiv, Ukraine
  • Department of Paediatric and Neonatology, Odessa State Medical University, Odessa Region Clinical Children's Hospital
    Odessa, Ukraine
  • Poltava regional children's clinical hospital, Ukranian stomatological academy, department of pediatrics
    Poltava, Ukraine
  • Pediatrics Crimean State Medical University Pulmonology, Department of Republican Clinical Children's Hospital
    Simferopol, Ukraine
  • Children's clinical hospital N.1, Zaporizzhya Medical Academy of post graduate education, department of pediatrics
    Zaporizhya, Ukraine
  • City Clinical Hospital N. 1 , Zaporizzhya Medical Academy of post graduate education, department of paediatrics
    Zaporizhya, Ukraine
  • Regional Children Clinical Hospital. Department of Pulmonology.
    Zaporizhya, Ukraine
08

References and documents

Publications

  • Papi A, Nicolini G, Baraldi E, Boner AL, Cutrera R, Rossi GA, Fabbri LM; BEclomethasone and Salbutamol Treatment (BEST) for Children Study Group. Regular vs prn nebulized treatment in wheeze preschool children. Allergy. 2009 Oct;64(10):1463-1471. doi: 10.1111/j.1398-9995.2009.02134.x. PubMed 19772514 ↗
  • Papi A, Nicolini G, Boner AL, Baraldi E, Cutrera R, Fabbri LM, Rossi GA. Short term efficacy of nebulized beclomethasone in mild-to-moderate wheezing episodes in pre-school children. Ital J Pediatr. 2011 Aug 22;37:39. doi: 10.1186/1824-7288-37-39. PubMed 21859484 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2007
First posted
Jul 6, 2007
Start
Mar 2006
CompletionActual
Jan 2007
Last update
Aug 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00497523
First posted
Jul 6, 2007
Start date
Mar 2006
Completion
Jan 2007
Last update
Aug 3, 2020

Study contacts

Renato Cutrera, MD
study chair · Department of Pediatric Medicine, Children's Hospital and Research Institute Bambino Gesù, Rome, Italy

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beclomethasone · Albuterol

Start the discussion